Form 8-K - Current report:
SEC Accession No. 0001641172-25-014621
Filing Date
2025-06-11
Accepted
2025-06-11 07:00:34
Documents
14
Period of Report
2025-06-10
Items
Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
Item 5.07: Submission of Matters to a Vote of Security Holders
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K form8-k.htm   iXBRL 8-K 62330
2 EX-10.1 ex10-1.htm EX-10.1 13244
  Complete submission text file 0001641172-25-014621.txt   293091

Data Files

Seq Description Document Type Size
3 XBRL SCHEMA FILE cing-20250610.xsd EX-101.SCH 3780
4 XBRL DEFINITION FILE cing-20250610_def.xml EX-101.DEF 26634
5 XBRL LABEL FILE cing-20250610_lab.xml EX-101.LAB 36717
6 XBRL PRESENTATION FILE cing-20250610_pre.xml EX-101.PRE 25258
16 EXTRACTED XBRL INSTANCE DOCUMENT form8-k_htm.xml XML 5937
Mailing Address 1901 W. 47TH PLACE KANSAS CITY KS 66205
Business Address 1901 W. 47TH PLACE KANSAS CITY KS 66205 (913) 942-2300
Cingulate Inc. (Filer) CIK: 0001862150 (see all company filings)

EIN.: 863825535 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-40874 | Film No.: 251038756
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)